myelofibrosis
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
myelofibrosis
Jul 2, 2024, 08:18 |
Blog
Naveen Pemmaraju: Navitoclax and Ruxolitinib in Patients With Untreated Myelofibrosis
Naveen Pemmaraju shared a post on LinkedIn: “A huge shout out to all of you…
Jun 18, 2024, 23:12 |
Insight
Koschmieder: Current standard and novel targets for myelofibrosis
Talha Badar shared on X: . "Koschmieder: current standard and novel targets…
Jun 15, 2024, 16:54 |
Blog
Our ongoing series “Current Thinking in Myelofibrosis” received The Spring 2024 Digital Health Award - PeerDirect
Ruben Mesa shared the following post by PeerDirect on LinkedIn: “So honored to have taken part…
Jun 15, 2024, 12:41 |
Blog
Naveen Pemmaraju: With MPN Guru and dear friend Prof Ruben Mesa at EHA2024
Naveen Pemmaraju recently shared a post on X: “Wonderful to be here at EHA2024 with MPN…
Jun 11, 2024, 14:59 |
Insight
Timos Papagatsias: EHA24 is expected to be one of the most exciting EHA conferences to-date!
Timos Papagatsias, CEO of LucidQuest shared a post on LinkedIn: “EHA24 is fast approaching and…
May 25, 2024, 09:12 |
Insight
Sankalp Arora: Excited to be presenting longterm follow up results of AZA + RUX in patients with myelofibrosis at ASCO24
Sankalp Arora, Heme/Onc fellow at MD Anderson Cancer Center, shared on X/Twitter: "The ASCO24 countdown begins!…
May 22, 2024, 03:21 |
Insight
Rahul Gosain: HemeSeries, with Naveen Pemmaraju we discuss treatment options and current landscape of Myelofibrosis
Rahul Gosain, Director of Regional Infusion Services at Wilmot Cancer Institute, shared on LinkedIn: “HemeSeries: with Naveen…
May 20, 2024, 05:51 |
Blog
Blood Cancers Today - Out now! The first MPN roundtable from HOPLive24.
Blood Cancers Today shared a post on LinkedIn: "Out now! The first MPN roundtable from HOPLive24.…
May 8, 2024, 01:20 |
Drugs
Talha Badar: Myelofibrosis after failure of Ruxolitinib
Talha Badar, Assistant Professor at Mayo Clinic Comprehensive Cancer Center shared a thread on Twitter/X:…
Apr 26, 2024, 08:09 |
Blog
Hagop Kantarjian: The results of the first clinical trial to explore activin receptor ligand traps of drugs in MF
Hagop Kantarjian, Leukaemia professor and Chair at MD Anderson Cancer Center, shared on X: ''Activin receptor…
Apr 13, 2024, 11:41 |
Insight
Nico Gagelmann: Methodological challenges in the development of endpoints for myelofibrosis clinical trials
Nico Gagelmann, Chair of CAR-T for plasma cell disorder committee and Chair Trainee Committee at…
Mar 31, 2024, 23:26 |
Blog
Naveen Pemmaraju: Delighted to share my The Bloodline Podcast for Patients & Caregivers
Naveen Pemmaraju recently shared a post on LinkedIn: “Delighted to share my The Bloodline Podcast for…
Feb 12, 2024, 16:02 |
Blog
Jean-Paul Kress: MorphoSys announced that it has entered into a business combination agreement to be acquired by Novartis
Jean-Paul Kress, CEO of MorphoSys, shared on LinkedIn: "Last week, MorphoSys announced that it has…
Jan 29, 2024, 14:55 |
Blog
David Almaguer: Don't forget that HSCT cures patients
David Almaguer, Professor of Hematology at Autonomous University of Nuevo León (UANL), shared on X/Twitter:…
Dec 31, 2023, 12:04 |
Blog
Key updates in the treatment and management of myeloproliferative neoplasms - Video Journal of Hematology and Hematological Oncology
Quoting Video Journal of Hematology and Hematological Oncology on LinkedIn: "NEW MPN Session from ASH23.…
Dec 1, 2023, 07:34 |
Drugs
David Steensma: Fascinating to see combination trials of ruxolitinib+ reading out in myelofibrosis
David Steensma, Chief Medical Officer of Ajax Therapeutics, posted on X/Twitter: “After so many years…
Nov 22, 2023, 02:47 |
Blog
Lucia Masarova: Let's tackle the inflammation in myelofibrosis! Era of combinational therapies is here
Lucia Masarova, Assistant Professor of the Department of Leukemia at MD Anderson Cancer Center, shared…
Sep 16, 2023, 18:02 |
Drugs
Ruben A. Mesa: Deeply excited by the Food and Drug Administration approval of Momelotinib for patients with myelofibrosis with anemia.
Quoting Ruben A. Mesa, the President of Atrium Health Levine Cancer, on X/Twitter: "Deeply excited…
Sep 8, 2023, 16:13 |
Societies
Naveen Pemmaraju: Delighted to be recognized by the Society of Hematologic Oncology for the Honorable Distinction Award
Naveen Pemmaraju, Leukemia Professor at the MD Anderson Cancer Center, shared on his Twitter account:…
Jul 3, 2023, 18:40 |
Blog
We propose molecular monitoring + donor lymphocyte infusion as standard of care for relapsed myelofibrosis after BMT
In a post by Nico Gagelmann on Twitter, it says, "We propose molecular monitoring +…
Jun 17, 2023, 15:37 |
Drugs
Super results in transfusion-dependent patients on ruxolitinib - Francesco Passamonti
It was a great honor to present at EHA 2023 on behalf of all investigators…
All:
21
Posts:
1 - 100
The largest philanthropic partnership in The V Foundation’s history - Dolphins Cancer Challenge
Glecirasib: A Promising Novel KRAS G12C Inhibitor in Clinical Development
How the Médecins Sans Frontières Journal Inspired a Lifetime of Humanitarian Service: Paul Spiegel
OncoDaily Party and Yvonne Award Photos - Part 1
Michael Douglas: The Untold Story of His Battle Against Cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube